Withdrawn ID: | 361 |
---|---|
Canonical SMILES: | |
Standard InChI: | |
Standard InChIKey: | |
ATC class(es): | D01AC06 |
P02CA02 | |
Molecular Formula: | C10H7N3S |
Molweight: | 201.248 |
Withdrawn due to drug safety reasons: | No |
---|---|
First approved: | 1967 |
First withdrawn: | 1995 |
Last withdrawn: | 1995 |
Total reported cases (submitted by medical professionals) with Thiabendazole as primary suspect: | 14 |
---|
Hospitalization (initial or prolonged): | 11 |
---|---|
Death: | 3 |
Life-Threatening condition: | 2 |
Side-effect | Case number |
---|---|
DRUG INEFFECTIVE | 5 |
Meningitis | 3 |
STRONGYLOIDIASIS | 2 |
INFECTION IN AN IMMUNOCOMPROMISED HOST | 1 |
LUNG DISORDER | 1 |
IMPETIGO | 1 |
HEPATOMEGALY | 1 |
HEADACHE | 1 |
ERYTHEMA NODOSUM | 1 |
EOSINOPHILIA | 1 |
EOSINOPHIL COUNT INCREASED | 1 |
ELECTROCARDIOGRAM QT PROLONGED | 1 |
DRUG ABUSER | 1 |
DIZZINESS | 1 |
DISEASE RECURRENCE | 1 |
DISEASE PROGRESSION | 1 |
CONVULSION | 1 |
CONJUNCTIVITIS | 1 |
BRADYCARDIA | 1 |
ADVERSE EVENT | 1 |
PYREXIA | 1 |
VERTIGO | 1 |
TOXIC EPIDERMAL NECROLYSIS | 1 |
THERAPY NON-RESPONDER | 1 |
STEVENS-JOHNSON SYNDROME | 1 |
SOMNOLENCE | 1 |
SKIN ODOUR ABNORMAL | 1 |
SKIN LESION | 1 |
RESPIRATORY FAILURE | 1 |
INFLAMMATION | 1 |
PNEUMONITIS | 1 |
OPTIC NEURITIS RETROBULBAR | 1 |
No therapeutic response | 1 |
Nausea | 1 |
MYOCARDIAL INFARCTION | 1 |
MOUTH ULCERATION | 1 |
Meningitis bacterial | 1 |
VOMITING | 1 |
Target UniProtKB ID | Activity in nm | Target Name | Target gene |
---|---|---|---|
O15118 | 3548.1 | NPC intracellular cholesterol transporter 1 | NPC1_HUMAN |
P04637 | 10000 | Cellular tumor antigen p53 | P53_HUMAN |
P51151 | 2511.9 | Ras-related protein Rab-9A | RAB9A_HUMAN |
P53582 | 3400 | Methionine aminopeptidase 1 | MAP11_HUMAN |
Q16637 | 6309.6 | Survival motor neuron protein | SMN_HUMAN |
Q16665 | 2511.9 | Hypoxia-inducible factor 1-alpha | HIF1A_HUMAN |
Toxicity class: | 5 |
---|---|
Toxicity type: | N/A |
LD50: | 2200 mg/kg |
ChEBML: | CHEMBL625 |
---|---|
DrugBank: | DB08630, DB00730 |